LIMITED OFFER
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code needed.
Formulation of Monoclonal Antibody Therapies
From Lab to Market
- 1st Edition - May 20, 2023
- Author: Amal Ali Elkordy
- Language: English
- Paperback ISBN:9 7 8 - 0 - 1 2 - 8 2 3 3 6 5 - 8
- eBook ISBN:9 7 8 - 0 - 1 2 - 8 2 3 4 2 8 - 0
Formulation of Monoclonal Antibody Therapies: From Lab to Market covers a wide range of topics about therapeutic monoclonal antibodies (mAbs) with a focus on formulation aspects.… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteFormulation of Monoclonal Antibody Therapies: From Lab to Market covers a wide range of topics about therapeutic monoclonal antibodies (mAbs) with a focus on formulation aspects. Therapeutic monoclonal antibodies are used for treatment of chronic diseases. It brings together a comprehensive knowledge in one accessible volume. Starting with foundational information on monoclonal antibodies, the book then discusses the importance of biopharmaceutical products, monoclonal antibodies, and biosimilars in treatment of chronic diseases, pharmaceutical aspects of mAbs, and how it can be administered. It also covers the industrial point of view and the clinical application of mAbs including in oncology, general medicine, rheumatology, hematology, dermatology, gastrointestinal tract, metabolic diseases, and dentistry. Formulation of Monoclonal Antibody Therapies: From Lab to Market is essential reading for researchers in biotechnology and biopharmaceutical fields, academics and pharmaceutical industrial scientists, and university students in pharmaceutical and biopharmaceutical sciences.
- Covers details of recent advances in using mAbs
- Examines how to overcome the challenges for formulations of therapeutic mAbs
- Includes clinical application of mAbs
Researchers in biotechnology/biopharmaceutical fields, academics and pharmaceutical industrial scientists, and advanced university students in pharmaceutical and biopharmaceutical sciences
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Chapter One. Introduction about monoclonal antibodies
- 1.1. Introduction
- 1.2. What are therapeutic antibodies?
- 1.3. Classification, types, and structures of mAb-based therapeutics
- 1.4. Nomenclature of therapeutic monoclonal antibodies
- 1.5. Production of monoclonal antibodies using various technologies
- 1.6. Mechanism of mAbs action and examples for mAbs with their clinical uses
- Chapter Two. Biosimilar antibodies
- 2.1. Introduction
- 2.2. Approval and market availability of biosimilar antibodies-based medicines
- 2.3. Differences between generic and biosimilar medicines
- 2.4. Importance of biosimilar mAbs
- Chapter THREE. Pharmaceutical aspects of mAbs: formulation, characterization, and current route of administration of monoclonal antibody therapies
- 3.1. Introduction: pharmaceutical formulations of lyophilized powder and liquid mAb dosage forms
- 3.2. Formulation of lyophilized mAb powder dosage forms
- 3.3. Formulation/preparation of mAbs in liquid dosage forms
- Chapter Four. Route of monoclonal antibodies administration
- 4.1. Introduction
- 4.2. Approaches for novel mAbs delivery systems to assist on mAb delivery by a route/s other than injections
- 4.3. Noninvasive routes for biologics including mAbs
- Chapter Five. Industrial aspects of finished monoclonal antibody therapies
- 5.1. Introduction
- 5.2. Glass vials
- 5.3. Prefilled syringes
- 5.4. Autoinjectors
- Chapter Six. Application of approved and marketed products of monoclonal antibody therapies
- 6.1. Introduction
- 6.2. Application of recently approved or in regulatory review mAb therapies in cancer
- 6.3. Application of recently approved or in regulatory review mAb therapies in noncancer diseases
- Index
- No. of pages: 346
- Language: English
- Edition: 1
- Published: May 20, 2023
- Imprint: Academic Press
- Paperback ISBN: 9780128233658
- eBook ISBN: 9780128234280
AE
Amal Ali Elkordy
His research is on the areas of formulation of macromolecules, solid dosage forms, gene therapy, niosomal nano-particulate systems and enhancement of dissolution of poorly-water soluble drugs and has received several awards and presented work at several national and international conferences. Research outcomes are reachable to non-specialist audiences as well as to experts in the field of pharmaceutics and are recognised both nationally and internationally as evidenced from the significantly publish of over 130 publications, including journal articles and conference papers, most of which are published in high-impact journals and well-cited. Dr Elkordy has extensive teaching experience incorporating research findings as “Research informs Teaching”. He designed MSc Pharmaceutical and BioPharmaceutical Formulations which is one of the few courses in the UK covering biopharmaceuticals as well as pharmaceuticals.
Affiliations and expertise
Professor of Pharmaceutics, Faculty of Health Sciences and Wellbeing, School of Pharmacy and Pharmaceutical Sciences, University of Sunderland, Sunderland, UKRead Formulation of Monoclonal Antibody Therapies on ScienceDirect